- Home
- TMQ vs EPIX Comparison
TMQ vs EPIX Comparison
Compare TMQ & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- EPIX
- Stock Information
- Founded
- TMQ 2004
- EPIX 2009
- Country
- TMQ Canada
- EPIX Canada
- Employees
- TMQ N/A
- EPIX N/A
- Industry
- TMQ Precious Metals
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- EPIX Health Care
- Exchange
- TMQ Nasdaq
- EPIX Nasdaq
- Market Cap
- TMQ 83.6M
- EPIX 77.2M
- IPO Year
- TMQ N/A
- EPIX N/A
- Fundamental
- Price
- TMQ $1.20
- EPIX $1.75
- Analyst Decision
- TMQ
- EPIX Hold
- Analyst Count
- TMQ 0
- EPIX 3
- Target Price
- TMQ N/A
- EPIX $2.00
- AVG Volume (30 Days)
- TMQ 224.1K
- EPIX 425.3K
- Earning Date
- TMQ 02-07-2025
- EPIX 02-11-2025
- Dividend Yield
- TMQ N/A
- EPIX N/A
- EPS Growth
- TMQ N/A
- EPIX N/A
- EPS
- TMQ N/A
- EPIX N/A
- Revenue
- TMQ N/A
- EPIX N/A
- Revenue This Year
- TMQ N/A
- EPIX N/A
- Revenue Next Year
- TMQ N/A
- EPIX N/A
- P/E Ratio
- TMQ N/A
- EPIX N/A
- Revenue Growth
- TMQ N/A
- EPIX N/A
- 52 Week Low
- TMQ $0.25
- EPIX $1.40
- 52 Week High
- TMQ $1.40
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- TMQ 57.45
- EPIX 41.97
- Support Level
- TMQ $1.10
- EPIX $1.70
- Resistance Level
- TMQ $1.24
- EPIX $1.85
- Average True Range (ATR)
- TMQ 0.06
- EPIX 0.10
- MACD
- TMQ -0.00
- EPIX 0.03
- Stochastic Oscillator
- TMQ 77.78
- EPIX 43.66
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.